Treatment of patients with advanced cancer with the natural killer cell line NK-92
Authors:
- Torsten TonnTTTorsten Tonn
- Dirk SchwabeDSDirk Schwabe
- Hans G. KlingemannHKHans G. Klingemann
- Sven BeckerSBSven Becker
- Ruth EsserRERuth Esser
- Ulrike KoehlUKUlrike Koehl
- Meinolf SuttorpMSMeinolf Suttorp
- Erhard SeifriedESErhard Seifried
- Oliver G. OttmannOOOliver G. Ottmann
- Gesine BugGBGesine Bug
- 1 December 2013
- journal article
- Published by Elsevier in Cytotherapy
- Vol. 15 (12) , 1563-1570
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Cellular therapy of cancer with natural killer cells—where do we stand?Cytotherapy, 2013
- Autologous stem cell transplant recipients tolerate haploidentical related‐donor natural killer cell–enriched infusionsTransfusion, 2012
- Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor RegressionClinical Cancer Research, 2011
- Innate or Adaptive Immunity? The Example of Natural Killer CellsScience, 2011
- Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemiaBlood, 2010
- Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cellsLeukemia Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative RegimensJournal of Clinical Oncology, 2008
- Up on the tightrope: natural killer cell activation and inhibitionNature Immunology, 2008
- Serial Killing of Tumor Cells by Human Natural Killer Cells – Enhancement by Therapeutic AntibodiesPLOS ONE, 2007